Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

被引：0
|
作者：
Claudia Dominici
Nicolas Sgarioto
Zhenbao Yu
Laura Sesma-Sanz
Jean-Yves Masson
Stéphane Richard
Noël J.-M. Raynal
机构：
[1] McGill University,Segal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology and Departments of Biochemistry, Human Genetics and Medicine
[2] Université de Montréal,Département de Pharmacologie et Physiologie
[3] and Research Centre of the Sainte-Justine University Hospital,Genome Stability Laboratory, CHU de Québec Research Center, Oncology Division, Department of Molecular Biology, Medical Biochemistry and Pathology
[4] Laval University Cancer Research Center,undefined
来源：
Clinical Epigenetics | 2021年 / 13卷
关键词：
Type I PRMT inhibitors; PARP inhibitors; MTAP; Drug resistance; Synergy; Non-small cell lung cancer cells; DNA damage; And cytotoxic;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
    Dominici, Claudia
    Sgarioto, Nicolas
    Yu, Zhenbao
    Sesma-Sanz, Laura
    Masson, Jean-Yves
    Richard, Stephane
    Raynal, Noel J. -M.
    CLINICAL EPIGENETICS, 2021, 13 (01)
  • [2] Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
    Michels, Judith
    Vitale, Ilio
    Senovilla, Laura
    Enot, David P.
    Garcia, Pauline
    Lissa, Delphine
    Olaussen, Ken A.
    Brenner, Catherine
    Soria, Jean-Charles
    Castedo, Maria
    Kroemer, Guido
    CELL CYCLE, 2013, 12 (06) : 877 - 883
  • [3] PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
    Levra, Matteo Giaj
    Olaussen, Ken Andre
    Novello, Silvia
    Soria, Jean-Charles
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (24) : 3875 - 3882
  • [4] Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors
    Ji, Wenchao
    Weng, Xiang
    Xu, Danhua
    Cai, Shufan
    Lou, Honggang
    Ding, Ling
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 522 (01) : 121 - 126
  • [5] The synergistic potential of PARP inhibitors and irinotecan in small cell lung cancer
    Oh, Songji
    Kim, Miso
    Kim, Soyeon
    Keam, Bhumsuk
    Youk, Jeonghwan
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    CANCER RESEARCH, 2024, 84 (06)
  • [6] The synergistic action of isolated sesquiterpene with cisplatin against non-small cell lung cancer cells
    Ahmed, A.
    Zehra, B.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S34 - S34
  • [7] Mechanisms of resistance to type I and type II MET inhibitors in non-small cell lung cancer
    Bahcall, Magda
    Kuang, Yanan
    Paweletz, Cloud P.
    Janne, Pasi A.
    CANCER RESEARCH, 2017, 77
  • [8] Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer
    Tsilingiri, Katerina
    Chalari, Anna
    Christopoulou, Georgia
    Voutsina, Alexandra
    Constantoulakis, Pantelis
    Potaris, Konstantinos
    Vamvakaris, Ioannis
    Hatzidaki, Dora
    Zachou, Georgina
    Vatsellas, Giannis
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    Klinakis, Apostolos
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [9] Action mechanism of talazoparib as a PARP inhibitor in non-small cell lung cancer cells
    Honda, Noritaka
    Tong, Ying
    Velu, Ankitha V.
    Saraswat, Barkha
    Watanabe, Masatoshi
    Bhone, Myat A.
    Taniguchi, Hirokazu
    Masutani, Mitsuko
    CANCER SCIENCE, 2025, 116 : 1402 - 1402
  • [10] EFFECTS OF HESPERIDIN ON NON-SMALL CELL LUNG CANCER CELLS
    Bireller, Elif Sinem
    Cincin, Zeynep Birsu
    Unlu, Miray
    Kiran, Bayram
    Baran, Yusuf
    Cakmakoglu, Bedia
    ANTICANCER RESEARCH, 2014, 34 (10) : 5837 - 5838
12345